Lithium-ion battery expert Prof. Paul Christensen queries claims made by LG Chem about finding the key to suppressing thermal ...
Citi lowered the firm’s price target on PTC (PTC) to $195 from $200 and keeps a Neutral rating on the shares ahead of the earnings report. The ...
Should I allow my child to use AI to better understand their homework? Since so much of this technology is new or rapidly changing, it can be difficult for parents to find concrete answers or to try ...
PTC PTC underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...
Inc., a leading provider of software solutions for product design, manufacturing, and service, continues to navigate a challenging macroeconomic environment while positioning itself for future growth.
The stock's fall snapped a two-day winning streak.
PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...
Barclays analyst Saket Kalia maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $215.00. The company’s ...
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results